Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
View/ Open
Date
2020-06-02ICR Author
Author
Chiu, M
Armstrong, EJL
Jennings, V
Foo, S
Crespo-Rodriguez, E
Bozhanova, G
Patin, EC
McLaughlin, M
Mansfield, D
Baker, G
Grove, L
Pedersen, M
Kyula, J
Roulstone, V
Wilkins, A
McDonald, F
Harrington, K
Melcher, A
Type
Journal Article
Metadata
Show full item recordAbstract
Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to some tumors cultivating an inherently 'cold' immune microenvironment. Oncolytic viruses (OV) have the capability to promote a 'hotter' immune microenvironment which can improve the efficacy of ICI.Areas covered: In this article we conducted a literature search through Pubmed/Medline to identify relevant articles in both the pre-clinical and clinical settings for combining OVs with ICIs and discuss the impact of this approach on treatment as well as changes within the tumor microenvironment. We also explore the future directions of this novel combination strategy.Expert opinion: The imminent results of the Phase 3 study combining pembrolizumab with or without T-Vec injection are eagerly awaited. OV/ICI combinations remain one of the most promising avenues to explore in the success of cancer immunotherapy.
Collections
Subject
Humans
Adenoviridae
Vaccinia virus
Enterovirus
Orthoreovirus
Neoplasms
Combined Modality Therapy
Oncolytic Virotherapy
Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
Research team
Targeted Therapy
Translational Immunotherapy
Language
eng
Date accepted
2020-02-10
License start date
2020-06
Citation
Expert opinion on biological therapy, 2020, 20 (6), pp. 635 - 652
Publisher
TAYLOR & FRANCIS LTD